Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04023552 · ClinicalTrials.gov registry record · Phase 3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
A Phase 3 study of Cardiovascular Disease and Lipoprotein(a), sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 8,323
- Enrollment target
- 20
- Study locations
NCT04023552 is a Phase 3 study of Cardiovascular Disease and Lipoprotein(a) that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 8,323 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT04023552, a Phase 3 study of Cardiovascular Disease and Lipoprotein(a), is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 8,323 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TQJ230
Study Locations (20)
Alabama
- SEC Clinical Research LLC - Andalusia
- Grandview Med Group Research LLC - Birmingham
- Novartis Investigative Site - Birmingham
- Heart Center Research Llc - Huntsville
- Novartis Investigative Site - Huntsville
- Mobile Heart Specialists - Mobile
- Novartis Investigative Site - Mobile
Arizona
- Novartis Investigative Site - Cottonwood
- Mercy Gilbert Medical Center - Gilbert
- Clinical Research Inst of Arizona - Sun City West
- Novartis Investigative Site - Sun City West
- Eclipse Clinical Research - Tucson
- Novartis Investigative Site - Tucson
California
- Cardiovascular Res Found - Beverly Hills
- National Heart Institute - Beverly Hills
- Novartis Investigative Site - Beverly Hills
- Flourish Clinical Resrch Covin - Covina
- Novartis Investigative Site - Covina
Arkansas
- Cardiology and Medicine Clinic PA - Little Rock
- Novartis Investigative Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,323 participants |
| Start Date | 2019-12-12 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04023552
The ClinicalTrials.gov registry entry for NCT04023552 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 8,323 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiovascular Disease and Lipoprotein(a) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04023552 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Alabama, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT04023552 about?
NCT04023552 is a clinical study titled "Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD". This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)
What is the current status of trial NCT04023552?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 8,323 participants. The study started on 2019-12-12. Estimated completion is 2026-06-30.
What conditions does trial NCT04023552 study?
This clinical trial studies the following conditions: Cardiovascular Disease and Lipoprotein(a).
What interventions are being tested in trial NCT04023552?
The interventions under investigation include: Placebo (DRUG), TQJ230 (DRUG).
Who is sponsoring clinical trial NCT04023552?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04023552 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.